Profile data is unavailable for this security.
About the company
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA α2, α3) receptor positive allosteric modulator for central nervous system (CNS) diseases; and IV tramadol, which is in phase III clinical development for the management of acute postoperative pain in adults in a medically supervised healthcare setting. AJ201 is a pleiotropic small molecule that is designed to modify multiple mechanisms including degradation of the abnormal AR protein and stimulation of Nrf1 and Nrf2, which are involved in protecting cells form oxidative stress which can lead to cell death. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties.
- Revenue in USD (TTM)0.00
- Net income in USD-5.87m
- Incorporated2015
- Employees3.00
- LocationAvenue Therapeutics Inc1111 KANE CONCOURSE, SUITE 301BAY HARBOR ISLANDS 33154United StatesUSA
- Phone+1 (781) 652-4500
- Fax+1 (302) 531-3150
- Websitehttps://avenuetx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biostax Corp | 0.00 | -1.51m | 2.72m | -- | -- | -- | -- | -- | -0.0181 | -0.0181 | 0.00 | -0.0633 | 0.00 | -- | -- | -- | -395.44 | -81.51 | -- | -- | -- | -- | -- | -- | -- | -4.04 | -- | -- | -- | -- | 53.32 | -- | -- | -- |
| Galera Therapeutics Inc | 0.00 | -29.11m | 2.72m | 7.00 | -- | -- | -- | -- | -0.5892 | -0.5892 | 0.00 | -2.54 | 0.00 | -- | -- | 0.00 | -90.03 | -83.69 | -119.01 | -97.54 | -- | -- | -- | -- | -- | -14.34 | 11.60 | -- | -- | -- | 5.05 | -- | -29.84 | -- |
| Palisade Bio Inc | 0.00 | -14.17m | 2.82m | 9.00 | -- | 0.2312 | -- | -- | -20.07 | -20.07 | 0.00 | 10.30 | 0.00 | -- | -- | 0.00 | -90.97 | -132.36 | -109.07 | -165.45 | -- | -- | -- | -27,892.32 | -- | -972.73 | 0.0339 | -- | -- | -0.7814 | 13.74 | -- | 18.53 | -- |
| Qualigen Therapeutics Inc | 0.00 | -9.27m | 2.89m | 4.00 | -- | -- | -- | -- | -82.94 | -87.60 | 0.00 | -22.25 | 0.00 | -- | -- | 0.00 | -134.64 | -- | -- | -- | -- | -- | -- | -- | -- | -9.64 | -- | -- | -- | -- | 10.22 | -- | -- | -- |
| Bluejay Diagnostics Inc | 0.00 | -9.40m | 2.90m | 10.00 | -- | 0.0323 | -- | -- | -44.53 | -44.53 | 0.00 | 3.34 | 0.00 | -- | -- | 0.00 | -97.27 | -- | -121.76 | -- | -- | -- | -- | -- | -- | -19.61 | 0.0185 | -- | -100.00 | -- | -7.07 | -- | -- | -- |
| Petros Pharmaceuticals Inc | 4.12m | -20.64m | 2.91m | 21.00 | -- | 0.3351 | -- | 0.7066 | -6.54 | -6.54 | 1.00 | 0.988 | 0.1529 | 0.6795 | 1.89 | 196,223.30 | -26.18 | -32.43 | -39.25 | -68.05 | 70.21 | 62.04 | -171.23 | -201.70 | 1.26 | -- | 0.4539 | -- | -2.83 | -16.15 | 31.06 | -- | -- | -- |
| Avenue Therapeutics Inc | 0.00 | -5.87m | 2.91m | 3.00 | -- | 0.5082 | -- | -- | -3.02 | -3.02 | 0.00 | 4.00 | 0.00 | -- | -- | 0.00 | -177.94 | -186.91 | -- | -287.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -192.15 | -- | -- | -- |
| Entero Therapeutics Inc | 0.00 | -9.69m | 2.95m | 15.00 | -- | 0.1999 | -- | -- | -15.29 | -15.87 | 0.00 | 24.07 | 0.00 | -- | -- | 0.00 | -20.88 | -295.92 | -26.29 | -1,599.51 | -- | -- | -- | -- | -- | -2,709.72 | 0.0025 | -- | -- | -- | -7.55 | -- | -- | -- |
| ENDRA Life Sciences Inc | 0.00 | -9.57m | 3.14m | 21.00 | -- | 0.0279 | -- | -- | -1,597.14 | -1,597.14 | 0.00 | 217.30 | 0.00 | -- | -- | 0.00 | -97.17 | -132.00 | -117.34 | -157.28 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.67 | -- | -19.46 | -- |
| ProtoKinetix, Inc. | 0.00 | -369.97k | 3.18m | 0.00 | -- | 7.83 | -- | -- | -0.0011 | -0.0011 | 0.00 | 0.0012 | 0.00 | -- | -- | -- | -78.67 | -696.88 | -85.20 | -785.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 78.22 | -- | 10.78 | -- |
| Tharimmune Inc | 0.00 | -8.88m | 3.19m | 2.00 | -- | 0.3517 | -- | -- | -55.46 | -55.46 | 0.00 | 6.11 | 0.00 | -- | -- | 0.00 | -138.06 | -- | -181.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.98 | -- | -- | -- |
| Talis Biomedical Corp | 408.00k | -51.03m | 3.21m | 99.00 | -- | 0.066 | -- | 7.86 | -28.02 | -28.02 | 0.224 | 26.69 | 0.0042 | -- | 1.53 | 4,121.21 | -52.13 | -68.18 | -57.23 | -74.22 | 95.10 | -- | -12,506.37 | -1,615.96 | -- | -- | 0.00 | -- | -55.65 | -2.24 | 45.13 | -- | -1.83 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 30 Jun 2024 | 75.00k | 5.24% |
| Sabby Management LLCas of 30 Jun 2024 | 37.39k | 2.61% |
| Moss Adams Wealth Advisors LLCas of 30 Sep 2024 | 11.00k | 0.77% |
| Tower Research Capital LLCas of 30 Jun 2024 | 3.21k | 0.22% |
| UBS Securities LLCas of 30 Jun 2024 | 673.00 | 0.05% |
| Wells Fargo Clearing Services LLCas of 30 Jun 2024 | 61.00 | 0.00% |
| EMFO LLCas of 30 Jun 2024 | 8.00 | 0.00% |
| RBC Dominion Securities, Inc.as of 30 Jun 2024 | 8.00 | 0.00% |
| Bank of America, NA (Private Banking)as of 30 Jun 2024 | 7.00 | 0.00% |
| JPMorgan Securities LLC (Investment Management)as of 30 Sep 2024 | 1.00 | 0.00% |
